Haematologica
HOME HELP FEEDBACK TABLE OF CONTENTS ARCHIVE SUBSCRIPTIONS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Mnjoyan, Z
Right arrow Articles by Afshar-Kharghan, V
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Mnjoyan, Z
Right arrow Articles by Afshar-Kharghan, V
Haematologica, Vol 91, Issue 3, 411-412
Copyright © 2006 by Ferrata Storti Foundation

Comparative Study

The effect of the JAK2 V617F mutation on PRV-1 expression

Z Mnjoyan, D Yoon, J Li, F Delhommeau, and V Afshar-Kharghan

JAK2(V617F)an acquired mutation of JAK2, is present in a majority of patients with polycythemia vera and to a lesser extent among patients with the other myeloproliferative disorders. We analyzed the effect of JAK2(V617F) on the expression of polycythemia rubra vera 1(PRV-1), using an in vitro model. Compared to wild-type JAK2, the presence of JAK2(V617F) increased both PRV-1 protein and mRNA levels in murine myeloid cells. A JAK2 inhibitor eliminated the V617F-induced increase in PRV-1 expression.


This article has been cited by other articles:


Home page
 ASH Education BookHome page
R. Skoda
The Genetic Basis of Myeloproliferative Disorders
Hematology, January 1, 2007; 2007(1): 1 - 10.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK TABLE OF CONTENTS ARCHIVE SUBSCRIPTIONS
Copyright © 2006 by the Ferrata Storti Foundation.